Ciena [CIEN]
Task 3 | investment-memo v1.4.2 | 2026-07-27 | Price $377.27
2026-07-29 — METHODOLOGY MIGRATION (supersedes parts of this document)
Written 2026-07-27 under the retired six-Gate / E[R]-vs-cash-hurdle framework; migrated onto the Criteria framework. The analysis below is retained as evidence; the following supersede it. The authoritative valuation output for this name is now §3A/§3B of
CIEN_Trade_Construction.md.Data basis
OLD NEW Revenue basis in the screen / scan / rescore path last fiscal year, FY2025 (ended 2025-11-01), 270 days stale TTM, 4 quarters to 2026-05-02 Revenue $4.770bn $5.343bn (+12.0%) EV / Sales 10.46x (EV / last-FY revenue) 9.34x Demonstrated revenue CAGR 9.5% (annual-FY) 11.6% (TTM-consistent) Implied-path margin −19.8pp −17.7pp Ciena is the control case for the last-FY error that understated MU by 136% and SanDisk by 76%: here it is only 12%, and correcting it does not change the conclusion. The artifact is severe precisely where revenue inflects fastest. Corrected inputs come from
reports/scan/CIEN_analysis.jsonand are used rather than recomputed.What is superseded
- §4's probability-weighted target of $253.99 and
E[R] for a long = −32.7% / short = +32.7%are retired, together with the 4.7% cash hurdle. The reverse-DCF implied-path test is now the ownership test: the price requires a 29.3% five-year revenue CAGR against 11.6% demonstrated — a margin of −17.7pp, FAIL.- Sensitivity is now run over the EXIT MULTIPLE, never over scenario probabilities. Note that the trade-construction document already found the probability axis unable to move the answer and said so; that finding is now the rule rather than an observation.
- The 5-year DCF-derived value of $89.91 is reclassified as a supporting cross-check and as an input to the Downside Criteria, not as a target. Terminal value is 68.3% of EV — above the 60% threshold at which the reverse DCF becomes mandatory as the primary instrument.
- A 12-month target is now required and is $415 (+18.5% vs spot $350.34), built on sourced FY2026 consensus revenue of $6.33bn at Ciena's own trailing-one-year median EV/Sales of 9.34x. §7's football field is retained as context but is no longer the valuation output.
- §2's peer-median comparison (EV/NTM sales 7.9x vs a 4.9x peer median) is demoted. Under
references/valuation.mda 12-month multiple must be anchored on the name's own range, not a peer median. The peer table survives under the Peer Spread Criteria, which is MEASURED and blocks nothing.- Price is now $350.34 (2026-07-28, scan), not the $377.27 used below.
Not superseded
The cancelable-backlog analysis, the RPO coverage series, the two-tranche contracted/merchant build, the reference-class work on FY2022→FY2024, and the base-rate discipline are all retained and remain the spine of the argument.
| $m | |
|---|---|
| Share price | $377.27 |
| Shares outstanding, basic (10-Q cover, 2026-05-02) | 141.6m |
| Market capitalisation | $53,421 |
| Total debt, PF for $2.875bn 0% converts due 2031 less ~$1.14bn term-loan repayment | 3,280 |
| Cash & investments, PF (estimate — Q3 10-Q not yet filed) | 2,765 |
| Net debt | 515 |
| Enterprise value | $53,936 |
Convertible initial conversion price $746.66 — 98% above spot, so no near-term dilution.
| Metric | CIEN | Peer median (ex-CIEN) | Premium |
|---|---|---|---|
| EV / NTM sales | 7.9x | 4.9x | +61% |
| P/E, NTM | 51.7x | 42.0x | +23% |
| EV / NTM EBITDA | 33.0x | 26.0x | +27% |
| P/E on FY2027E adj. EPS (house $8.36) | 45.1x | — | — |
Peer set: LITE 9.2x / 52x, ANET 15.0x / 46x, COHR 4.3x / 42x, FN 4.0x / 33x, CSCO 5.5x / 18x, NOK 1.1x / 17x. Peer multiples are estimates from public market data as of 2026-07-27, not computed from filings — flagged as such.
Context that matters: Ciena carries a 44.8% gross margin hardware model. ANET's 15x EV/sales rests on a 63% gross margin and software attach; CSCO's 5.5x on 66%. Ciena is being valued closer to the software-margin cohort on hardware economics.
| FY | GAAP op margin | Adjusted op margin |
|---|---|---|
| FY2022 | 6.1% | ~10.4% |
| FY2023 | 8.2% | ~15.0% |
| FY2024 | 4.2% | ~12.0% |
| FY2025 | 4.2% | ~10.5% |
| FY2026E (guide) | ~14.4% | 19.0% |
| FY2027E (house base) | ~17.6% | 21.7% |
The FY2026 guide implies an operating margin Ciena has never achieved in its history. The house base case then assumes it goes higher. This is a generous model, not a punitive one — worth stating plainly before reading the downside conclusions.
Scenarios, verified in Excel)| FY2027E revenue | y/y | FY2027E adj. EPS | Exit multiple | Target | Return | P | |
|---|---|---|---|---|---|---|---|
| Bull | $8,505m | +35.0% | $11.29 | 42x | $474.33 | +25.7% | 30% |
| Base | $7,402m | +17.5% | $8.36 | 28x | $234.02 | −38.0% | 40% |
| Bear | $5,903m | −6.3% | $3.77 | 16x | $60.27 | −84.0% | 30% |
Probability-weighted target $253.99. E[R] for a long = −32.7%; for a short = +32.7%.
Base-rate check on each scenario. Bull (+35%) exceeds any two-year run in Ciena's history and requires the full cancelable tranche to convert — allowed, but named as above-base-rate. Base (+17.5%) is close to Ciena's FY2023 (+20.7%) backlog-consumption year. Bear (−6.3%) is milder than the actual FY2024 outcome (−8.5%) that followed the last backlog peak — i.e. the bear case is the reference-class outcome, not a catastrophe assumption. The bear target of $60 is not a fantasy: CIEN's 52-week low is $86.64, reached within the last twelve months.
| FY2026E | FY2027E | FY2028E | |
|---|---|---|---|
| Contracted tranche (RPO-backed, Tier 1) | $1,038m | $1,038m | $425m |
| Merchant tranche (cancelable + book-to-revenue, Tier 3/4) | $5,262m | $6,365m | $7,644m |
| Contracted share of revenue | 16.5% | 14.0% | 5.3% |
The contracted share declines across the horizon, which is the honest expression of uncertainty the method requires. At no point does contractual evidence support more than ~17% of modelled revenue.
Principle 5 check — does this have the signature of a real regime change? No, and it fails in the diagnostic direction. A genuine contractual regime change raises the floor more than the ceiling. Here the contractual floor is only ~$2.5bn against a $6.3bn revenue run-rate, so the floor is low relative to the headline, while the bull case is driven entirely by demand narrative. That is narrative wearing an evidence costume — the argument is about demand, not structure.
WACC 12.30% (Rf 4.25%, ERP 5.5%, beta 1.55 blended — the computed 1-year beta is 2.53, which would give a far higher WACC; the blended figure is deliberately conservative), terminal growth 3.0%.
| $m | |
|---|---|
| Sum of PV of explicit FCF (FY26–FY30) | 4,317 |
| PV of terminal value | 9,351 |
| Enterprise value | 13,668 |
| Equity value | 13,153 |
| DCF value per share | $89.91 |
| vs spot | −76.2% |
| Terminal value as % of EV | 68.3% |
Sensitivity — every cell in the grid is below spot:
| WACC \ g | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |
|---|---|---|---|---|---|
| 7.5% | $161 | $175 | $197 | $228 | $238 |
| 8.5% | $129 | $138 | $150 | $166 | $189 |
| 9.5% | $107 | $113 | $121 | $132 | $147 |
| 10.5% | $91 | $96 | $101 | $108 | $118 |
| 11.5% | $79 | $82 | $87 | $92 | $112 |
Even at a 7.5% WACC and 4% perpetual growth — assumptions that would be aggressive for a cyclical hardware vendor — the DCF returns $238, still 37% below spot.
| Method | Low | Mid | High |
|---|---|---|---|
| DCF (WACC/g band) | $90 | $90 | $238 |
| Scenario-weighted | $60 | $254 | $474 |
| P/E on FY2027E adj. EPS (17x/27x/38x) | $142 | $226 | $318 |
| EV/Sales on FY2027E (3.5x/5.5x/8.0x) | $93 | $249 | $405 |
| Street consensus target | $270 | $565.71 | $720 |
| Spot | $377.27 |
Spot sits above the top of every method's range except the Street's.
references/consensus-bridge.md — required)Street position. Consensus rating Buy; average target $565.71 (20 analysts, S&P Global via stockanalysis.com); range $270–$720. Mix: 13 buy/strong-buy (65%), 6 hold (30%), 1 sell (5%). FY2026 consensus revenue $6.33bn, EPS $6.54 (15 analysts). Last updated 2026-06-23.
The most important fact about this consensus: the market is not paying it. The stock is $377.27 against a $565.71 mean target — a 33% discount to consensus. The Street has not marked down its targets since the June print; the market has. When price and consensus diverge this far, the marginal price-setter is already discounting something the published targets are not.
Numbers-vs-multiple decomposition of the house divergence:
| House | Street | Gap | Driver | |
|---|---|---|---|---|
| FY2026 revenue | $6,300m | $6,330m | −0.5% | no disagreement |
| FY2026 adj. EPS | $6.23 | $6.54 | −4.7% | tax/share-count detail, not a thesis |
| FY2027 revenue | $7,402m | ≈$8,500–9,000m (DERIVED) | −13% to −18% | cancelable-backlog conversion rate |
| FY2027 adj. EPS | $8.36 | ≈$11.3–12.6 (DERIVED) | −26% to −33% | flow-through of the above |
| Applied multiple, FY2027E | 28x (base) | ~45–50x | — | de-rating toward hardware norms |
The divergence is roughly two-thirds numbers, one-third multiple. That matters: this is not a valuation-only argument.
Named weakness — this is the memo's softest joint. The FY2027 Street figures above are derived, not sourced. Alpha Vantage EARNINGS_ESTIMATES returned an empty array for CIEN; stockanalysis.com puts FY2027 behind a paywall; Yahoo Finance's analysis page returned HTTP 503. The derivation backs FY2027 EPS out of the $565.71 target at the 45–50x multiple the stock currently commands. It is a reasonable inference and it is not a sourced consensus number, and Consensus Criteria is qualified accordingly.
All computed from SEC XBRL (FY2025 vs FY2024) and Alpaca SIP bars. These reproduce the 2026-07-27 screen exactly — F-score 7/9, GP/A 0.34, accruals −0.12, asset growth +4% — which validates both pipelines.
| Factor | Value | Reading for a SHORT |
|---|---|---|
| 12-1 momentum | +510% | Strongly against — top-percentile |
| % of 52-week high | 60% ($627 high, 2026-06-02) | Favourable — not near highs |
| 3-month return | −25.5% | Favourable — trend has cracked |
| Price vs 50-day MA | −21.3% | Favourable |
| Price vs 200-day MA | +8.6% ($347.33) | Mildly against, converging |
| Gross profitability (GP/A) | 0.34 | Against — solid |
| Sloan accruals ((NI−CFO)/avg assets) | −11.9% | Against — high earnings quality |
| Piotroski F-score | 7/9 | Against — healthy (fails only current ratio and gross margin) |
| Asset growth | +4.0% | Neutral/favourable — no bloat |
| Short interest / days-to-cover | 3.6% / 1.5d | Favourable — uncrowded, easy borrow |
| Realised vol (30/60/90/252d) | 68.5 / 76.9 / 78.8 / 69.9% | High — sizing constraint |
| Beta (1yr daily vs SPY) | 2.53 | High |
The scorecard majority argues against the short. Per Quality Criteria's corroboration standard, that raises the evidentiary bar for the narrative case rather than lowering it — addressed directly in the trade-construction note.
Correlations (1yr daily): COHR 0.711, FN 0.675, LITE 0.672, AAOI 0.532 (matches the screen's 0.532 exactly), ANET 0.443, CSCO 0.304.